Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells
ShangJie Wu*1, Shu Duan1, ShuiPing Zhao1, Ying Cai2, Ping Chen2 and Xiang Fang3

Address: 1Division of Cardiovascular Disease, Department of Internal Medicine, The Second Xiangya Hospital, Center Southern University, Changsha, Hunan, China, 2Division of Respiratory Disease, Department of Internal Medicine, The Second Xiangya Hospital, Center Southern University, Changsha, Hunan, China and 3Department of Biochemistry, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Email: ShangJie Wu* - wu_shangjie@hotmail.com; Shu Duan - duanshu321@hotmail.com; ShuiPing Zhao - zhaosp@medmail.com.cn; Ying Cai - caiying5540@sina.com; Ping Chen - chenping101@hotmail.com; Xiang Fang - xiang-fang@uiowa.edu
* Corresponding author

Abstract
Objective: To explore the effects of atorvastatin on expression of cyclooxygenase-2 (COX-2) in human pulmonary epithelial cells (A549).

Methods: A549 cells were incubated in DMEM medium containing lipopolysaccharide (LPS) in the presence or absence of atorvastatin. After incubation, the medium was collected and the amount of prostaglandin E2 (PGE2) was measured by enzyme-linked immunoassay (ELISA). The cells were harvested, and COX-2 mRNA and protein were analyzed by RT-PCR and western-blot respectively.

Results: LPS increased the expression of COX-2 mRNA and production of PGE2 in a dose- and time-dependent manner in A549. Induction of COX-2 mRNA and protein by LPS were inhibited by atorvastatin in a dose-dependent manner. Atorvastatin also significantly decreased LPS-induced production of PGE2. There was a positive correlation between reduced COX-2 mRNA and decreased PGE2 (r = 0.947, P < 0.05).

Conclusion: Atorvastatin down-regulates LPS-induced expression of the COX-2 and consequently inhibits production of PGE2 in cultured A549 cells.

1. Introduction
Human pulmonary epithelial cell is one of major sources of productive inflammatory biomediators, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), in respiratory inflammatory diseases [1]. Cyclooxygenase-2 (COX-2) is an inducible enzyme that is expressed in response to inflammatory cytokines, and it is responsible for the synthesis of pro-inflammatory PGs such as PGE2. Increased expression of COX-2 and production of PGE2 have been found in pulmonary inflammatory disorders [2].

Statins is a class of compounds that decreases cholesterol synthesis via inhibition of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase. Recently, anti-
inflammatory effects of statins have been described [3]. For example, Atorvastatin reduces expression of the COX-2 in cultured vascular smooth muscle cells [4]. However, it is not clear whether Atorvastatin also affects COX-2 expression in human pulmonary epithelial cells. Because of importance of COX-2 in inflammatory respiratory diseases, we tested the effects of Atorvastatin on lipopolysaccharide (LPS)-induced expression of COX-2 in cultured human pulmonary epithelial cells.

2. Methods

2.1 Materials

Human pulmonary epithelial cell line (A549) was purchased from American Type Culture Collection (ATCC). Medium DMEM, trypsin, fetal bovine serum (FBS) and LPS were purchased from Sigma-Aldrich. ECL chemiluminescence reagents, COX-2 polyclonal antibody were purchased from Cayman Chemical Co. Anti-rabbit IgG, horseradish peroxidase linked whole antibody was obtained from Amersham LIFE SCIENCE. HECAMEG was from Vegatec (Villejuif, France). Trizol and electrophoresis reagents were from Promag Co. Atorvastatin was a gift from Beijing Honghui Medicine Co.

2.2 Cell culture

A549 cells were grown in DEEM medium supplemented with 5% FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 50 µg/L amphotericin B. Cells were sub-cultured into six-well plates and maintained until sub-confluence. The medium was then replaced by a serum-free culture medium for 24 h prior to the addition of LPS and/or other reagents. The cells were then incubated with various concentrations of LPS for 9 h, or 10 µg LPS for different times. For atorvastatin experiments, the cells were incubated in the serum-free medium containing 10 µg LPS in the presence or absence of different concentrations of atorvastatin for 9 h.

2.3 PGE2 assay

After incubation, the medium was collected for measurement of PGE2. PGE2 was determined by enzyme-linked immunosorbent assays (ELISA, Shanghai Sun Biomedical Co. CV <10%).

2.4 RNA extraction, reverse transcription-polymerase chain reaction (RT-PCR)

COX-2 mRNA was measured by RT-PCR as previously described [5]. Briefly, total RNA from different experimental conditions was obtained by Trizol method (Life technologies) and the concentration of RNA was determined by an absorbance at 260 nm. For RT-PCR, 100 ng of RNA from different experimental conditions was applied to the access RT-PCR System. The following primers were used for COX-2: forward: 5’-AAG CTG GGA AGC CIT CTC TA-3’ and reverse: 5’-TTT CCA TCC TTG AAA AGG CGC-3’, which yielded products of 342 bp (50 sec at 55°C for annealing of the primers, 35 cycles), and CYCLOPHILIN A: forward: 5’-ATG TGC AAC CCC GTG TCT TTC G-3’ and reverse: 5’-CGT GTG AAG TCA CCA CCC TGA CAC A-3’, which yielded products of 206 bp (50 sec at 55°C for annealing primers, 38 cycles). The DNA products from RT-PCR reactions were analyzed on a 4% polyacrylamide-urea gel in the same buffer. The polyacrylamide gels were dried and scanned using the ImageQuant densitometer (Gel Doc 2000, BioRad Co).

2.5 Western Blot analysis

After incubation, A549 cells were washed twice in phosphate-buffered saline, lysed in 200 µl lysis buffer (20 mM Tris/HCL, pH 7.5, 20 mM HECAMEG, 1 mM benzamidine). Protein content was determined by a microbicinchoninic acid assay (Pierce) with bovine serum albumin as standard. Western blot analysis was performed as described previously [6]. Briefly, the protein was separated by electrophoresis on a 10% polyacrylamide gel at 180 V for 45 min. After transfer to nitrocellulose, the membrane was blocked, incubated with a specific rabbit polyclonal antibody against COX-2 (1:1000). The blots were then incubated with a horseradish peroxidase-conjugated donkey anti-rabbit antibody (1:5000). Antibody labeling was detected by enhanced chemiluminescence. The films were scanned using an Arcus II Agfa scanner, and densitometric analysis was performed using Sigma Gel software.

2.6 Statistical analysis

Statistical analysis was performed with SPSS analysis (SPSS10.0 Software). PGE2 and RT-PCR data are presented as mean ± S.D., and the differences between the multiple treatment groups were analyzed by the one-way ANOVA, LSD test. Data were correlated by nonparametric Spearman’s rank method. Probability values of 0.05 or less were considered to be statistically significant.

3. Results

3.1 Dose- and time-dependent effects of LPS on COX-2 mRNA expression and PGE2 production

To determine the concentration dependent effect of LPS, A549 cells were incubated with various concentrations of LPS for 9 h. RT-PCR analysis indicated that LPS increased the expression of COX-2 mRNA in a concentration-dependent manner (Figure 1A, top). Concentrations as low as 5 µg/ml LPS were effective in inducing expression of the COX-2 mRNA. To determine the time-dependent effect, A549 cells were incubated with LPS (10 µg/ml) for different times. The expression of COX-2 mRNA was increased by LPS as early as 6 h, the earliest time point tested. It reached a maximum induction by 9 h of incubation, and remained stable for at least 12 h, the longest time tested (Figure 1B, middle). LPS also increased the
A: Dose-dependent effect of LPS on COX-2 mRNA expression. A549 cells were incubated with various concentrations of LPS for 9 h (top, * P < 0.05 vs LPS 5 µg/ml).

B: Time-dependent effect of LPS on COX-2 mRNA expression. A549 cells were incubated with LPS (10 µg/ml) for various times (middle, * P < 0.05 vs 6 hrs group; • P < 0.05 vs 5 µg/ml LPS group; # P < 0.01 vs non-LPS group; P < 0.05 vs 6 h group). These data were representative of three separate experiments.

C: Time- and dose-dependent effects of LPS on PGE₂ production (bottom, * P < 0.05 vs non-LPS group; • P < 0.05 vs 5 µg/ml LPS group; # P < 0.01 vs non-LPS group; * P < 0.05 vs 6 h group).

Figure 1
A: Dose-dependent effect of LPS on COX-2 mRNA expression. A549 cells were incubated with various concentrations of LPS for 9 h (top, * P < 0.05 vs LPS 5 µg/ml). B: Time-dependent effect of LPS on COX-2 mRNA expression. A549 cells were incubated with LPS (10 µg/ml) for various times (middle, * P < 0.05 vs 6 hrs group). C: Time- and dose-dependent effects of LPS on PGE₂ production (bottom, * P < 0.05 vs non-LPS group; • P < 0.05 vs 5 µg/ml LPS group; # P < 0.01 vs non-LPS group; * P < 0.05 vs 6 h group). These data were representative of three separate experiments.
production of PGE₂, a major cyclooxygenase product in A549 cells, in a time- and dose-dependent manner (Figure 1C, bottom). LPS (5 μg/ml) caused a 3-fold increase in amount of PGE₂, and increased PGE₂ was also observed as early as 6 h of incubation.

3.2 Effect of atorvastatin on LPS-induced expression of COX-2 mRNA and protein

To determine whether atorvastatin affect the LPS-induced expression of COX-2, the cells were incubated with various concentrations of atorvastatin for 9 h in the presence of 10 μg/ml LPS. RT-PCR analysis indicated that LPS-induced expression of the COX-2 mRNA was decreased significantly by atorvastatin (Figure 2). Consistent with this observation, LPS-induced expression of the COX-2 protein was also inhibited by atorvastatin (Figure 3). Atorvastatin inhibited LPS-induced expression of COX-2 mRNA and protein in a dose-dependent manner.

3.3 Effect of atorvastatin on LPD-induced PGE₂ production

Because atorvastatin decreased the expression of COX-2 mRNA and protein, we determined whether it also blocks PGE₂ production. A549 cells were incubated with various concentrations of atorvastatin in the presence of 10 μg/ml LPS for 9 hrs. After incubation, the medium was collected, and the amount of PGE₂ in the medium was detected by
As shown in Table 1, atorvastatin decreased LPS-induced PGE2 production in a dose-dependent manner.

### 3.4 Correlations

According to Spearman’s non-parametric rank correlation method, data analysis revealed that atorvastatin-mediated reduction of LPS-induced expression of COX-2 is correlated with a decrease in PGE2 production ($r = 0.947$, $P < 0.05$).

### 3.5 Time-dependent effects of atorvastatin on LPS-induced COX-2 expression and PGE2 production

We further investigated the time-dependent effect of atorvastatin on expression of COX-2 and PGE2 production. A549 cells were incubated with 10 µM atorvastatin in the presence of 10 µg/ml LPS for various times. Atorvastatin decreased the expression of COX-2 mRNA, protein, and PGE2 in a time-dependent manner (Figure 4). The result showed the similar time-dependent patterns in atorvastatin-mediated reduction of COX-2 mRNA, protein and PGE2, further suggesting a relationship between COX-2 expression and PGE2 production.

### 4. Discussion

Inflammatory cytokines as well as prostaglandins (PGs) play important roles in inflammatory process of respiratory system [7]. PGs are synthesized from arachidonic acid by a reaction catalyzed by cyclooxygenase. Two isoforms of this enzyme have been identified [8]. COX-1 is expressed constitutively in almost all tissues [9], and COX-2 is an inducible enzyme that is expressed in response to inflammatory cytokines [10]. Increased expression of COX-2 has been reported in human pulmonary epithelial cells under experimental inflammatory conditions [11]. In the present study, we also found that LPS induces expression of COX-2 mRNA and PGE2 formation in a dose- and time-dependent manner in A549 cells. These results suggested that expression of the COX-2 could be induced in A549 cells. Because the COX-2 is responsible for the synthesis of pro-inflammatory PGs such as PGE2 [10,11], an increased expression of COX-2 might play an important role in respiratory inflammatory processes.

HMG-CoA reductase inhibitors, which decrease the synthesis of cholesterol, have been shown to decrease the incidence of acute coronary events [12]. Recent studies suggest that the beneficial effects of statins on clinical events may be not related to its' effect on cholesterol synthesis. Statins affect endothelial cells, smooth muscle cells, monocyte/macrophage, vasomotor function, inflammatory responses, and plaque stability [13,14]. Anti-inflammatory action of statins might be related to the reduction of the production of pro-inflammatory cytokines. Statins inhibit the Ang II-induced secretion of interleukin-6 (IL-6) in cultured human vascular smooth muscle cells, and decrease production of IL-6, interleukin-1β in human umbilical vein endothelial cells [15]. Atorvastatin also down-regulates expression of COX-2 mRNA both in vivo and in vitro [4]. In this study, we found that atorvastatin significantly reduced LPS-induced expression of COX-2 mRNA in cultured A549 cells. Atorvastatin also significantly reduced LPS-induced PGE2 production.
production. The correlation analysis indicated that there is a positive correlation between reduced expression of COX-2 and decreased PGE2. Furthermore, the patterns showing effects of atorvastatin on LPS-induced expression of COX-2 mRNA, protein and PGE2 production in different times were similar. These suggest that decreased production of PGE2 by atorvastatin is caused by down-regulation of COX-2 expression. In contrast to our observations, other study [16] showed that mevastatin and lovastatin increase expression of COX-2 and subsequent prostacyclin formation in human aortic smooth muscle cells. It appears that the effects of statins on expression of COX-2 might depend on the cell types or different statins used.

In conclusion, atorvastatin down-regulates LPS-induced expression of COX-2 and production of PGE2 in cultured A549 cells. These results suggest that HMG-CoA reductase inhibitors might have beneficial effects against respiratory inflammation.

References
1. Arnold R, Humbert B, Werchau H, et al.: Interleukin-8, interleukin-6, and soluble tumor necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. *Immunology* 1994, 82:126-33.
2. Jane AM, Simonlarkin, Timothy JW: Cyclooxygenase-2: regulation and relevance in inflammation. *Biochem Pharmacol* 1995, 50:1535-1542.
3. Dichl WD, Dulak J, Frick M, et al.: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 2003, 23:58-63.
4. Hernandez-Presa Miguel Angel, Martin-Ventura Jose Luis, Ortega Monica, et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. *Atherosclerosis* 2002, 160:49-58.
5. Mitchell JA, Belvisi MG, Alakraseeennon P, et al. Induction of cyclooxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. *Br J Pharmacol* 1994, 113:1008-14.
6. Fang X, Chen P, Moore SA: The oxygen radical scavenger pyrrolidine dithiocarbamate enhances interleukin-1beta-induced cyclooxygenase-2 expression in cerebral microvascular smooth muscle cells. *Microvasc Res* 2002, 64:405-13.
7. Albazzaz MK, Pal C, Berman P, et al.: Inflammatory markers of lower respiratory tract infection in elderly people. *Age Aging* 1994, 23:299-302.
8. Adler KB, Fischer BM, Wright DT, et al.: Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation. *Ann N Y Acad Sci* 1994, 725:128-45.
9. Raz A, Wyche A, Siegel N, et al.: Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. *J Biol Chem* 1988, 263:3022-8.
10. Dubois RN, Abramson SB, Crofford L, et al.: Cyclooxygenase in biology and disease. *FASEB J* 1998, 12:1063-73.
11. Simon L: Role and regulation of cyclooxygenase-2 during inflammation. *Am J Med* 1999, 106:375-425.
12. The 4S investigators: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994, 344:1383-89.
13. Bellosta S, Bernini F, Ferri N, et al.: Direct vascular effects of HMG-CoA reductase inhibitors. *Atherosclerosis* 1998, 137:S101-S109.
14. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than lower cholesterol. *Lancet* 1996, 348:1079-1082.
15. Bonetti PO, Lerman LO, Napoli C, et al.: Statin effects beyond lipid lowering—are they clinically relevant? *Eur Heart J* 2003, 24:225-248.
16. Degraeve F, Bolla M, Blaie S, et al.: Modulation of COX-2 expression by statins in human aortic smooth muscle cells. *J Biol Chem* 2001, 276:46849-46855.
17. Mitchell JA, Larkin S, Williams TJ: Cyclooxygenase-2: regulation and relevance in inflammation. *Biochemical Pharmacology* 1995, 50:1535-1542.